PE-Labeled Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 (0.03% Proclin)

用户评价
货号-规格
价格
Qty.
FABm038-01-200tests (50tests X 4)
¥2000.00
合计0件 产品金额¥ 0

产品详情

  • 抗体来源(Source)

    Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 is a chimeric monoclonal antibody recombinantly produced from CHO cells, which combines the variable region of a human monoclonal antibody with mouse IgG1 constant domain, which provides higher batch consistency and long term security of supply.

  • 应用(Application)

    Flow Cytometry (Detection the expression of 4-1BB on Human cells).

  • 种属(Species)

    Rabbit

  • 亚型(Isotype)

    Mouse IgG1 | Mouse Kappa

  • 特异性(Specificity)

    This product is a specific antibody specifically reacts with 4-1BB protein.

  • 种属反应性(Reactivity)

    Human

  • 偶联(Conjugate)

    PE

    Excitation Wavelength: 488 nm / 561 nm

    Emission Wavelength: 575 nm

  • 同型对照(Isotype Control)

    The Isotype control is sold separately and you can search for Cat. No. DNP-PM1 for product information.

  • 推荐稀释比(Recommended Dilution)

    1:20

  • 制剂(Formulation)

    Supplied as 0.2 μm filtered solution in PBS, pH7.4, 0.03% Proclin300, 0.2% BSA with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 存储(Storage)

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. Store at 2-8 °C for 12 months.
  • 运输(Shipping)

    This product is supplied and shipped with blue ice, please inquire the shipping cost.

  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 活性(Bioactivity)-FACS

     4-1BB FACS

    Flow cytometric analysis of HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line staining with PE-Labeled Monoclonal Anti-Human 4-1BB Antibody, Mouse IgG1 (Cat. No. FABm038-01) at 1:20 dilution (5 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).

    Protocol

用户评价
发表评论

背景介绍

4-1BB, also known as CD137 and TNFRSF9, is an approximately 30 kDa transmembrane glycoprotein in the TNF receptor superfamily. 4-1BB functions in the development and activation of multiple immune cells. Mature human 4-1BB consists of a 163 amino acid (aa) extracellular domain (ECD) with four TNFR cysteine-rich repeats, a 27 aa transmembrane segment, and a 42 aa cytoplasmic domain . Within the ECD, human 4-1BB shares 60% aa sequence identity with mouse and rat 4-1BB. 4-1BB is expressed as a disulfide-linked homodimer on various populations of activated T cell including CD4, CD8, memory CD8, NKT, and regulatory T cells as well as on myeloid and mast cell progenitors, dendritic cells, mast cells, and bacterially infected osteoblasts . It binds with high affinity to the transmembrane 4-1BB Ligand/TNFSF9 which is expressed on antigen presenting cells and myeloid progenitor cells . This interaction costimulates the proliferation, activation, and/or survival of the 4-1BB expressing cell . It can also enhance the activation-induced cell death of repetitively stimulated T cells . Mice lacking 4-1BB show augmented T cell activation, perhaps due to its absence on regulatory T cells . 4-1BB can associate with OX40 on activated T cells, forming a complex that responds to either ligand and inhibits Treg and CD8 T cell proliferation . Reverse signaling through 4-1BB Ligand inhibits the development of dendritic cells, B cells, and osteoclasts but supports mature dendritic cell survival and costimulates the proliferation and activation of mast cells.
4-1BB activation enhances CD8 T cell and NK cell mediated anti-tumor immunity . It also contributes to the development of inflammation in high fat diet-induced metabolic syndrome . Soluble forms of 4-1BB and 4-1BB Ligand circulate at elevated levels in the serum of rheumatoid arthritis and hematologic cancer patients, respectively .

前沿进展

 
药物研发进展
  • 英文全称:

    Tumor necrosis factor receptor superfamily member 9

  • 中文全称:

    肿瘤坏死因子受体超家族成员9

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    74 详情

  • 最高研发阶段:

    临床二期

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍